Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA

/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the...

Related Keywords

California , United States , Texas , San Carlos , Mike Brophy , Phil Halloran , Brian Symmons , Natera Inc , Alberta Transplant Applied Genomics Centre , Drug Administration , Natera Organ Health , Nasdaq , Clinical Laboratory Improvement Amendments , Prnewswire Natera Inc , Corporate Affairs , Prospera Kidney , Alberta Transplant Applied Genomics , Molecular Microscope , Diagnostic System , Banff Classification , Allograft Pathology , Morgan Health , Natera , Nc ,